Literature DB >> 28734193

Improved 225Ac daughter retention in InPO4 containing polymersomes.

R M de Kruijff1, K Drost2, L Thijssen3, A Morgenstern4, F Bruchertseifer4, D Lathouwers2, H T Wolterbeek2, A G Denkova5.   

Abstract

Alpha-emitting radionuclides like actinium-225 (225Ac) are ideal candidates for the treatment of small metastasised tumours, where the long half-life of 225Ac enables it to also reach less accessible tumours. The main challenge lies in retaining the recoiled alpha-emitting daughter nuclides, which are decoupled from targeting agents upon emission of an alpha particle and can subsequently cause unwanted toxicity to healthy tissue. Polymersomes, vesicles composed of amphiphilic block copolymers, are capable of transporting (radio)pharmaceuticals to tumours, and are ideal candidates for the retention of these daughter nuclides. In this study, the Geant4 Monte Carlo simulation package was used to simulate ideal vesicle designs. Vesicles containing an InPO4 nanoparticle in the core were found to have the highest recoil retention, and were subsequently synthesized in the lab. The recoil retention of two of the daughter nuclides, namely francium-221 (221Fr) and bismuth-213 (213Bi) was determined at different vesicle sizes. Recoil retention was found to have improved significantly, from 37 ± 4% and 22 ± 1% to 57 ± 5% and 40 ± 2% for 221Fr and 213Bi respectively for 100nm polymersomes, as compared to earlier published results by Wang et al. where 225Ac was encapsulated using a hydrophilic chelate (Wang et al. 2014). To better understand the different parameters influencing daughter retention, simulation data was expanded to include vesicle polydispersity and nanoparticle position within the polymersome. The high retention of the recoiling daughters and the 225Ac itself makes this vesicle design very suitable for future in vivo verification.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2017        PMID: 28734193     DOI: 10.1016/j.apradiso.2017.07.030

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  5 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

Review 2.  A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy.

Authors:  Uwe Holzwarth; Isaac Ojea Jimenez; Luigi Calzolai
Journal:  EJNMMI Radiopharm Chem       Date:  2018-05-30

Review 3.  Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.

Authors:  Ján Kozempel; Olga Mokhodoeva; Martin Vlk
Journal:  Molecules       Date:  2018-03-05       Impact factor: 4.411

Review 4.  Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy.

Authors:  Joshua Loya; Charlie Zhang; Emily Cox; Achal S Achrol; Santosh Kesari
Journal:  CNS Oncol       Date:  2019-11-21

5.  Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy.

Authors:  Stefan J Roobol; Thomas A Hartjes; Johan A Slotman; Robin M de Kruijff; Guzman Torrelo; Tsion E Abraham; Frank Bruchertseifer; Alfred Morgenstern; Roland Kanaar; Dik C van Gent; Adriaan B Houtsmuller; Antonia G Denkova; Martin E van Royen; Jeroen Essers
Journal:  Nanotheranostics       Date:  2020-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.